(5-039) Incidence and Management of Cytokine Release Syndrome and Neurotoxicity in Acute Lymphoblastic Leukemia Patients with Minimal Residual Disease Receiving Blinatumomab
Monday, December 5, 2022
4:15 PM – 5:15 PM
Location: Bayside A, Level 1
Category: Evaluative Study Topic: Drug Information/Drug Use Evaluation
Co-Author(s): Summer Byerley, Katelyn Kennedy, Mallory Stevens, Kelly Plach
